PD-L1 expression in metaplastic breast carcinoma using the PD-L1 SP142 assay and concordance among PD-L1 immunohistochemical assays Journal Article
| Authors: | Grabenstetter, A.; Jungbluth, A. A.; Frosina, D.; Hoda, R.; Dos Anjos, C. H.; Patil, S.; Sevilimedu, V.; Weigelt, B.; Reis-Filho, J. S.; Zhang, H.; Traina, T.; Robson, M. E.; Brogi, E.; Wen, H. Y. |
| Article Title: | PD-L1 expression in metaplastic breast carcinoma using the PD-L1 SP142 assay and concordance among PD-L1 immunohistochemical assays |
| Abstract: | Immunotherapy for the treatment of programmed death-ligand 1 (PD-L1) positive locally advanced or metastatic triple negative breast cancer may benefit patients with metaplastic breast cancer (MpBC). Previous study of PD-L1 in MpBC scored tumor cells (TCs), different from Food and Drug Administration-approved scoring methods. We sought to define PD-L1 expression in MpBCs and to evaluate concordance of 3 PD-L1 assays. Primary, treatment naive MpBC treated at our Center from 1998 to 2019 were identified. PD-L1 expression was assessed using SP142, E1L3n, and 73-10. We evaluated PD-L1 expression on tumor infiltrating immune cells (IC) and also in TCs. For each assay, we scored PD-L1 expression using ≥1% IC expression according to the IMpassion130 trial criteria and using combined positive score (CPS) ≥10 according to the KEYNOTE-355 trial cutoff. A total of 42 MpBCs were identified. Most MpBC had PD-L1 positivity in ≥1% IC with all 3 assays (95%, 95%, 86%) in contrast to a maximum 71% with a CPS ≥10. PD-L1 IC expression was comparable between the SP142 and 73-10 assays and was lowest with E1L3n. PD-L1 TC expression was lowest using SP142. The overall concordance for IC scoring was 88% while 62% had concordant CPS. For each assay, the results of the 2 scoring algorithms were not interchangeable. The SP142 assay showed distinct expression patterns between IC (granular, dot-like) and TC (membranous) while 73-10 and E1L3n showed membranous and/or cytoplasmic expression in both IC and TC. Most MpBC in our cohort were positive for PD-L1 indicating eligibility for anti-PD-L1/programmed death-1 immunotherapy. © 2021 Lippincott Williams and Wilkins. All rights reserved. |
| Keywords: | immunohistochemistry; triple negative; programmed death-ligand 1; sp142; 73-10; metaplastic breast carcinoma; e1l3n |
| Journal Title: | American Journal of Surgical Pathology |
| Volume: | 45 |
| Issue: | 9 |
| ISSN: | 0147-5185 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2021-09-01 |
| Start Page: | 1274 |
| End Page: | 1281 |
| Language: | English |
| DOI: | 10.1097/pas.0000000000001760 |
| PUBMED: | 34115674 |
| PROVIDER: | scopus |
| PMCID: | PMC9437740 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 October 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work